Literature DB >> 16729971

Elevated expression of ERK 2 in human tumor cells chronically treated with PD98059.

Shigeru Kanda1, Hiroshi Kanetake, Yasuyoshi Miyata.   

Abstract

We examined the effect of chronic exposure of tumor cells to a mitogen-activated protein kinase/extracellular signal-regulated kinases (ERK) kinase inhibitor, PD98059, on cell proliferation was investigated. Human renal carcinoma cells (ACHN) and prostatic carcinoma cells (DU145) were cultured in the presence of PD98059 for more than 4 weeks (denoted ACHN (PD) cells and DU145 (PD) cells, respectively) and proliferation and signal transduction pathways were examined. PD98059 significantly inhibited the proliferation of parental cells. However, PD98059 failed to inhibit proliferation of ACHN (PD) and DU145 (PD) cells significantly. Expression of ERK 1 and 2 was elevated in these cells. These phenotypes were reversible. Downregulation of ERK 2, but not ERK 1, by small interfering RNA significantly inhibited the proliferation of ACHN (PD) and DU145 (PD) cells. Taken together, chronic exposure of tumor cells to PD98059 induced elevated expression of ERK 2, which was associated with decreased sensitivity of cellular proliferation to PD98059.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16729971     DOI: 10.1016/j.bbrc.2006.05.048

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  3 in total

1.  Downregulation of the c-Fes protein-tyrosine kinase inhibits the proliferation of human renal carcinoma cells.

Authors:  Shigeru Kanda; Yasuyoshi Miyata; Hiroshi Kanetake; Thomas E Smithgall
Journal:  Int J Oncol       Date:  2009-01       Impact factor: 5.650

2.  Long-term exposure of human renal carcinoma cells to PD98059 induces epithelial-mesenchymal transition-like phenotype and enhanced motility.

Authors:  Shigeru Kanda; Hiroshi Kanetake; Yasuyoshi Miyata
Journal:  Mol Cell Biochem       Date:  2007-11-14       Impact factor: 3.396

3.  Loss of PTEN function may account for reduced proliferation pathway sensitivity to LY294002 in human prostate and bladder cancer cells.

Authors:  Shigeru Kanda; Hiroshi Kanetake; Yasuyoshi Miyata
Journal:  J Cancer Res Clin Oncol       Date:  2008-08-23       Impact factor: 4.553

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.